BioSpace News Archive

Muscle stimulator is a device that induces an electrical impulse to strengthen the weak muscles by triggering muscle contractions. It is also known as electrical muscle stimulator or neuromuscular electrical stimulator.

As per a report published by National Cancer Institute, in 2012, lung cancer accounted for approximately 160,340 deaths across the country and around 220,160 new lung cancer cases were diagnosed in the same year.

The face shield market may reach for the escalator to great growth opportunities across the forecast period of 2019-2029. The COVID-19 pandemic may serve as the prime reason for the growth of the face shield market.

Evotec SE announced that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company.

Appointment strengthens the financial and corporate experience of Metrion’s Board in support of the Company’s planned international growth

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, announces that Christian Hoyer Millar has joined the Company’s Board as a Non-Executive Director.

At an upcoming webinar on April 21, 2021, Dr. Lars Sennerby will review his simplified protocols using Neoss ProActive® Edge Implants, which are designed to ensure predictable stability in challenging clinical cases.

Funding will support first-in-man intravenous studies to tackle antibiotic resistant Pseudomonas aeruginosa in ventilated associated pneumonia

Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE, a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate.

Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced the initiation of dosing in a Phase 2 proof-of-concept trial in patients with head and neck squamous cell carcinoma.